(1)	Wafergen Bio-Systems, Inc (WGBS.OB), a Nevada USA incorporated company with a registered address and place of business at Bayside Technology Center, ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇, ▇▇▇ (“Existing Shareholder”);

and

(2)	Malaysian Technology Development Corporation Sdn Bhd (Company No 235796-U), a company incorporated in Malaysia with a registered address at ▇▇▇▇▇ ▇-▇, ▇▇▇▇▇▇ Yayasan ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ (“MTDC);

and

(3)	Wafergen Biosystems (M) Sdn Bhd (formerly known as Global Dupleks Sdn Bhd) (Company No 795066-H), a company incorporated in Malaysia with a registered address at ▇▇▇▇ ▇-▇▇-▇, ▇▇▇▇▇ ▇▇▇▇▇▇ 11, ▇▇ ▇▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ (“Company”).

Recitals

(A)	The Company is a private company limited by shares incorporated under the laws of Malaysia and has at the date of this Agreement an authorised share capital of RM100,000 divided into 100,000 ordinary shares of RM1.00 each .

(B)	The Existing Shareholder is the legal and beneficial owner of the entire issued and paid-up share capital of the Company of RM2 divided into 2 ordinary shares of RM1.00 each.

(C)	The Company shall increase its authorised share capital from RM100,000 divided into 100,000 ordinary shares of RM1.00 each, to RM10,000,000 divided into 8,000,000 ordinary shares of RM1.00 each and 200,000,000 redeemable convertible preference shares of RM0.01 each.

(D)	The Existing Shareholder and the Investor are desirous of undertaking the Business through the Company and agree to regulate their relationship as shareholders of the Company in accordance with the terms and conditions of this Agreement.

(E)

The Existing Shareholder and the Company intend to raise up to USD3,500,000 in multiple tranches. The Existing Shareholder and the Company have requested the Investor to, and the Investor has agreed to, participate in the Company by way of subscription for the RCPS upon the terms and subject to the conditions set out in this Agreement.

It is agreed as follows:

1 Definitions and Interpretations

1.1 Definitions

In this Agreement, unless the context otherwise requires:

Act	means the Companies ▇▇▇ ▇▇▇▇;
Articles	means the articles of association of the Company;
Board	means the board of directors of the Company;
Business	means the business of the Company as defined in Clause 8.1;
Conversion Shares	means the Shares resulting from the conversion of the RCPS, such Conversion Shares to rank pari passu in all respects with all other then existing Shares, and “Conversion Share” means one of the Conversion Shares;
Director	means any director of the Company appointed on the Board including, where applicable, any alternate director;
Initial Closing	means twenty one (21) days from the date of this Agreement or such later date as the Parties may mutually agree on;
IPO	means the listing of the Company on any approved stock exchange;
Investor	means MTDC, and any other person acceding to this Agreement;
Encumbrance	means any mortgage, charge, pledge, lien, assignment, hypothecation, security interest, title retention, right of first refusal, pre-emption right, option, preferential right or trust arrangement or other security arrangement or agreement conferring a right to a priority of payment;
RCPS	means Series A Redeemable Convertible Preference Shares of the Company with principal terms as set out in Schedule 1;
Parties	means the Existing Shareholder, the Investor and the Company, and “Party” refers to any one (1) of them;
Series A Director	means the director as defined in Clause 6.1;
Shareholders	means the shareholders of the Company from time to time;
Shares	means ordinary shares of RM1.00 each in the share capital of the Company, and “Share” refers to any one (1) of them;
Subscription Price	means the Ringgit Malaysia equivalent to USD2.25 calculated at the prevailing exchange rate on the date payment of the Subscription Price is effected, payable by the Investor for each RCPS under this Agreement, out of which RM0.01 is to be paid towards the par value of each RCPS and the difference between the Subscription Price and the par value of RM0.01 (constituting the subscription premium) is to be credited to the share premium account of the Company;
Subsequent Closing	means upon fulfilment of the milestones provided for in Clause 3.1.1(b);
Tranche A Shares	means 444,444 new RCPS of RM0.01 each in the Company to be issued at an issue price in Ringgit Malaysia equivalent to USD2.25 each;
Tranche B Shares	means 444,444 new RCPS of RM0.01 each in the Company to be issued at an issue price in Ringgit Malaysia equivalent to USD2.25 each; and
Warranties	means the representations and warranties made by the Investor, the Existing Shareholder and the Company, as set out in Schedule 2.

1.2 Interpretation

In this Agreement, unless the context otherwise requires:

(a)

headings and underlining are for convenience only and do not affect the interpretation of this Agreement;

(b)

words importing the singular include the plural and vice versa;

(c)

words importing a gender include any gender;

(d)

an expression importing a natural person includes any corporation or other body corporate, partnership, association, governmental agency, two or more persons having a joint or common interest, or any other legal or commercial entity or undertaking;

(e)

a reference to a party to a document includes that party's successors and permitted assigns;

(f)

any part of speech or grammatical form of a word or phrase defined in this Agreement has a corresponding meaning; and

(g)

a warranty, representation, covenant or agreement on the part of two or more persons binds them jointly and severally.

2. Conditions Precedent

2.1 Conditionality

The subscription for the RCPS by the Investor is subject to, and conditional upon, the fulfilment of the following conditions precedent within 21 days from the date of this Agreement (subject to extension by agreement of the Parties):

(a)

the approval of the investment committee of the Investor;

(b)

the Investor being satisfied with the results of their investigation or due diligence exercise on the Company;

(c)

the signing of a put agreement between the Existing Shareholder and MTDC;

(d)

the signing of the put option agreement between ▇▇▇▇▇▇ ▇▇▇▇▇▇ and MTDC;

(e)

increase in the paid up share capital in the Company by the Existing Shareholder to at least RM300,000 in cash or otherwise, in accordance with Clause 3.2.1; and

(f)

there being no material adverse change in the operations or financial conditions of the Company or the Existing Shareholder prior to Initial Closing.

2.2 Waiver

To the extent permitted by law, the Parties reserve the right to agree in writing to mutually waive the fulfilment of any conditions precedent in Clause 2.1.

2.3 Non-fulfillment

Unless specifically waived under Clause 2.2, if any conditions precedent is not fulfilled within 21 days after the date of this Agreement (or such later date as the Parties may mutually agree on):

(a)

this Agreement shall automatically cease and terminate;

(b)

all obligations and liabilities of the parties under this Agreement shall cease to have effect; and

(c)

none of the parties shall have any claim against any other party in relation to this Agreement,

but notwithstanding anything to the contrary in this Clause, a party shall be liable for any antecedent breach of this Agreement.

3. Share Capital

3.1 Subscription for Preference Shares

3.1.1

Subject to the terms and conditions of this Agreement, the Investor shall subscribe in cash up to a maximum of 888,888 RCPS, allocated across several tranches as follows:

(a)

at Initial Closing, MTDC will subscribe for Tranche A Shares, and the Company will allot and issue Tranche A Shares to MTDC, free from any Encumbrance; and

(b)

upon fulfilment of the following milestones:

(i)

delivery of the Smartchip Alpha System to the University of Pittsburgh; and

(ii)

the publication of the results from the University of Pittsburgh,

(“Subsequent Closing”), the Investor will subscribe for Tranche B Shares, and the Company will allot and issue Tranche B Shares to the Investor, free from any Encumbrance.

3.1.2

The Investor shall subscribe for the amount of shares and consideration as follows:

Name of Investor	Tranche A		Tranche B		Total
	No. of RCPS	Consider-ation (USD)	No. of RCPS	Consider-ation (USD)	No. of RCPS	Consider-ation (USD)
MTDC	444,444	1,000,000	444,444	1,000,000	888,888	2,000,000

The principal terms of the RCPS are set out in Schedule 1.

3.1.3

In respect of each subscription for RCPS under this Agreement, the Company will issue a Subscription Notice to the Investor. The Subscription Notice will specify the number of RCPS to be subscribed by the Investor under Tranche A at the Initial Closing, and Tranche B at the Subsequent Closing, and the Subscription Price.

3.1.4

The Existing Shareholder irrevocably confirms its waiver of all rights of pre-emption whatsoever that it may have in connection with the issue and conversion of the RCPS to the Investor pursuant to the terms of this Agreement.

3.1.5

The Company shall endeavour to raise a further USD1.5 million through the issue of RCPS within one year from the Initial Closing. The Investor irrevocably confirms its waiver of all rights of pre-emption whatsoever that it may have in connection with the issue and conversion of such RCPS.

3.2 Subscription for Shares

3.2.1

Prior to the Initial Closing, and subject to all other conditions precedent in Clause 2.1 being fulfilled, the Company shall increase its issued and paid-up share capital from RM2 to RM300,000 by way of allotment and issue of 299,998 Shares and the Existing Shareholder shall subscribe and satisfy the subscription money for such Shares by cash or otherwise. The Investor agrees that the manner of satisfaction of such subscription money may include capitalisation of amounts owing from the Company to the Existing Shareholder, or other consideration otherwise than in cash.

4. Subscription Completion Date

4.1	Subject to fulfilment of all conditions precedent in Clause 2.1, the completion of each allotment and issue of the RCPS to the Investor pursuant to this Agreement shall take place at the registered office of the Company as follows:

(a) Tranche A Shares at the Initial Closing; and

(b) Tranche B Shares at the Subsequent Closing;

or such other date and time as may be mutually agreed by the Parties in writing.

4.2

The Investors shall cause or procure a cheque, bank draft or cashier’s order in favour of the Company to be deposited, or a telegraphic or electronic transfer made, to the bank account of the Company held with HSBC Bank Berhad for the total subscription monies payable for the number of RCPS to be subscribed (as set out in the relevant Subscription Notice), in exchange for the delivery by the Company of the following:

(a)

at the Initial Closing, the share certificates in respect of the RCPS, a certified extract of the shareholders' resolution of the Company approving the subscription of the Tranche A Shares by MTDC at the Initial Closing (including amendment of the Articles of Association of the Company where required), pursuant to the terms and subject to the conditions of this Agreement;

(b)

at the Subsequent Closing, the share certificates in respect of the RCPS, a certified extract of the shareholders' resolution of the Company approving the subscription of the Tranche B Shares by MTDC at the Subsequent Closing, pursuant to the terms and subject to the conditions of this Agreement; and

(c)

at both the Initial Closing and the Subsequent Closing, a certified extract of the resolution of the Board confirming the allotment and issue of the relevant number of RCPS to be subscribed by MTDC pursuant to the relevant Subscription Notice.

5.	Undertakings, Warranties and Representations by the Parties

5.1

Subject to any exceptions expressly and specifically disclosed in any correspondence, communication, document or information in writing prior to or after the execution of this Agreement and prior to the completion of the subscription of the RCPS, the Parties warrant to each other that the information and statements set out in the Warranties are true, accurate and correct in all respects at the date of this Agreement. To this effect, the Warranties will be deemed to be repeated during this period as if they had been entered into afresh during the said period in relation to the facts and circumstances then existing.

5.2	The Parties acknowledge and agree that each of them entered into this Agreement in reliance on the Warranties.

5.3	Each of the Warranties is separate and is to be construed independently of the others and is not limited by reference to any of the other Warranties.

Save as disclosed to the Investors in any correspondence, communication, document or information in writing prior to or after the execution of this Agreement and prior to the Completion of this Agreement, no information relating to the RCPS or the Company will limit the nature of the Warranties given by the Company under this Agreement, or will prejudice any claim to be made by the Investors against the Company for any breach of the Warranties.

Each of the Party will indemnify and will keep the other Parties indemnified against all losses, damages, costs and expenses which the other Parties may incur or be liable for in respect of any claim, demand, liability, action, proceedings or suits arising out of or in connection with :

(a)

a breach of a Warranty;

(b)

any Warranty not being true and correct in all respects; or

(c)

any Warranty being misleading in any respect,

save and except where any of the matters set out in paragraphs 5.1 to 5.3 above shall have been apparent in any correspondence, communication, document or information in writing and disclosed or provided to the Investors prior to or after the execution of this Agreement and prior to the Completion of this Agreement.

6. Management of the Company

6.1 Board of Directors

The Board shall comprise 6 directors of which:

(a)

MTDC shall have the right to appoint one (1) director (“Series ADirector”) and MTDC shall procure that (if relevant), the Series A Director shall, prior to his appointment as a director of the Company, provide a confidentiality and non-competition undertaking to the Company; and

(b)

the Existing Shareholder shall have the right to appoint five (5) directors and such right shall include the appointment of the Chief Executive Officer.

MTDC shall have the right to nominate an alternate to the Series A Director and the Existing Shareholder shall have the right to nominate an alternate director to such directors appointed under paragraph 6.1(b).

MTDC and the Existing Shareholder will jointly appoint an independent director to the Board with the requirement that the independent director has relevant international industry experience in the Business.

The right of appointment of the Series A Director shall include the right for MTDC to remove such person at any time from such office and also the right to determine from time to time the period which such person shall hold office as the Series A Director. Upon MTDC ceasing to be a shareholder in the Company, MTDC shall simultaneously procure the resignation of the Series A Director. The Series A Director may not be removed by the Existing Shareholder or any other party except when MTDC ceases to be a shareholder in the Company. Any appointment or removal of the Series A Director by MTDC shall be made in writing and shall be delivered to the registered office of the Company.

6.2 Board Meetings

The quorum at all meetings shall be at least three (3) Directors and must include the Series A Director (or his alternate). If a quorum is not present within 45 minutes after the time appointed for the commencement of a meeting of the Board, that meeting shall be adjourned to the same time 7 days after that meeting at the same place provided that at such adjourned meeting (for the same agenda), the quorum shall be any two (2) Directors.

The Directors may meet together either in person or by telephone, radio, video conference or similar communication equipment or any other form of audio or audio-visual instantaneous communication by which all persons participating in the meeting are able to hear and be heard by all other participants and participation in a meeting pursuant to this provision shall constitute presence in person at such meeting.

The Company’s Articles shall be amended to provide that a quorum of the Board must include at least one Series A Director, except at any adjourned meeting.

6.3 Provisions in respect of meetings

Any Director may at any time request for a meeting to be convened, subject to the Board meeting at least once quarterly unless otherwise agreed to by a vote of a majority of Directors including at least one vote from a Series A Director. The request for a meeting must be made in writing and delivered to the company secretary of the Company.

Upon receiving the request, the company secretary is to issue a notice, giving at least 7 days’ prior written notice to all Directors and their alternates. The notice shall set out the date, time, venue and the agenda or matters to be discussed for the Board meeting. Such notice shall not be required if all Directors are present or

represented at the meeting or if the absent Directors agree in writing to waive the requirement of such notice.

6.4	Resolutions

So long as a quorum is present throughout the meeting of the Board in accordance with clause 6.2, all resolutions or decisions of the Board are to be by a simple majority of all the Directors present and capable of voting at the meeting of the Board.

6.5 Circular resolution

A written resolution or minute of a decision made by the Board which is signed by all the Directors is regarded as valid and effectual as if it had been passed at a duly convened Board meeting. Any such written resolution or minute may consist of several documents (or facsimiles thereof) in like form or in one or more counterparts, each signed by one or more of the Directors, and all counterparts taken together constitute one document.

6.6 No shareholding requirement

The Directors need not be shareholders of the Company and are not liable to retire by rotation until removed/replaced by the Party nominating them.

6.7 Management

The operations of the Company will be managed by the Board, but the day to day administration or management of the Company may be vested in a management committee (“Management Committee”) appointed by the Board from time to time who shall at all times be responsible and subject to the control of the Board. The Management Committee may comprise members of the Board.

6.8 Nominees

The parties acknowledge that as the Series A Director is a nominee of MTDC, the Series A Director shall be entitled to report all matters concerning the Company, including but not limited to matters discussed at any meeting of the Board, to MTDC and its shareholders and that the Series A Director may take advice and obtain instructions MTDC.

The Company agrees to indemnify and keep the Series A Director indemnified, subject to section 140 of the Act..

7. General meetings

7.1 General meetings

Annual general meetings and extraordinary general meetings of the Shareholders are to be held in accordance with the provisions of the Act.

7.2 Quorum

The quorum for all general meetings of the Shareholders is two (2) persons being present throughout the meeting, consisting of the Shareholders or their respective proxy, attorney or authorised representative.

7.3 Decisions at meetings of the Shareholders

7.3.1

Ordinary Resolution

So long as a quorum is present throughout the meeting of the Shareholders in accordance with clause 7.2, subject to clause 7.4, a simple majority vote of those present and voting suffices to pass an ordinary resolution.

7.3.2

Special Resolution

The approval of Shareholders by way of special resolution (as defined in the Act) is required for matters which require a special resolution to be passed as specified in the Act.

7.4 Shareholder Reserve Matters

The resolutions in relation to the following matters require approval from all Shareholders present and voting at a general meeting or by circular resolution (signed by all the Shareholders):

(a)

any amendment to the Memorandum and Articles of Association of the Company;

(b)

the appointment or removal of any Director or senior management of the Company; and

(c)

the declaration of dividends by the Company.

8. Business of the Company

8.1

The core business of the Company, unless otherwise agreed in writing by the Investors, shall be developing, manufacturing, and distributing state of the art solutions for Gene Analysis (Gene Expression, and Genotyping) and stem cell research and cell biology (“Business”). The Company will not engage in any other business which detracts from, or is not complementary to, the Business.

8.2	The Business is to be carried out in accordance with all applicable laws and requirements.

8.3

The Shareholders shall use its reasonable endeavours without being required to incur any further financial obligation (other than as expressly set out in this Agreement) to promote the interests of the Company. The Business is to be conducted in the Shareholders’ and the Company’s best interests on sound commercial profit-making principles so as to generate the maximum achievable maintainable profits available for distribution, and otherwise in accordance with the general principles as varied from time to time by agreement in writing between the Parties.

8.4	The Company shall not, and the Existing Shareholder shall ensure that the Company shall not, without the prior written consent of the Investors or as expressly stated in this Agreement :

(a)

cease to conduct or carry on its Business substantially as now conducted and/or acquire or dispose of or dilute any interest in any other business, company, partnership or sole proprietorship; and

(b)

purchase, sell, mortgage or charge any substantial asset, or property or any material interest in those assets or property or sell or dispose of the whole or a substantial part of the undertaking and goodwill or the assets of the Company.

8.5 The Existing Shareholder and/or the Company shall ensure that :

(a)

the Company shall at all times carry on and conduct its business in a proper and efficient manner;

(b)

each employee and consultant of the Company enters into a confidential information and inventions agreement (in a form acceptable to the Investor) with the Company;

(c)

the Company shall submit to the Investor without being formally requested:

(i)

an annual budget and operating plan no later than sixty (60) days prior to the commencement of each fiscal year;

(ii)

an annual business plan;

(iii)

audited financial statements on an interim and annual basis; and

(iv)	monthly reports, including financial reports, bank statements and technical reports.

The obligation of the Company to furnish the information set out in paragraph 8.5(c) will cease when the Company completes its IPO or becomes subject to the reporting provisions of any applicable stock exchange requirements or MTDC ceasing to be a shareholder in the Company.

(d)

at all times keep true accurate and up to date books and records of all the affairs of the Company;

(e)

supply to the Investor such information relating to the Company as it may require and without prejudice to the foregoing shall keep the Investor fully and promptly informed as to all material developments regarding the Company’s financial and business affairs and promptly notify the Investor of any significant litigation or arbitration affecting or likely to affect the Company and of any bona fide offer to purchase or subscribe any share capital of the Company;

(f)

at all times be adequately insured in respect of the assets of the company which are of an insurable nature and obtain life insurance for the core management team of the Company, the proceeds of which are payable to the Company; and

(g)

upon the Company’s receipt of reasonable notice, the Investor may have access during normal business hours to relevant non-confidential information and/or non-competitive information requested by the Investor

including the right to visit the Company’s business premises and inspect the Company’s record books.

9 New Issues of Shares

9.1 New Issues by Company

The Shareholders agree that any new Shares and/or RCPS issued by the Company must be with the prior approval of the Shareholders (“Offered Shares”) and the Offered Shares shall be first offered to each of the Shareholders in proportion to each of their shareholding in the Company at the time of the proposed new issue other than:

(i)	for the initial share capital as provided for in Clauses 3.1 and 3.2;

(ii)	the issuance of Shares and/or RCPS referred to in Clause 3.1.5;

(iii)

the Conversion Shares, where applicable;

(iv)	Shares issued pursuant to employee share option plans approved by a majority of the Board;

(v)	Shares issued for merger or acquisition transactions; or

(vi)	any issuance excepted from the right of first refusal by a majority of the Board.

9.2 Offer to Shareholders

An offer of the Offered Shares shall be made by notice specifying the number of new Shares and/or RCPS offered, the subscription price and limiting a period (not being less than 30 days) within which the offer, if not accepted, will be deemed to be declined. Upon the expiration of such period the Board shall offer the Offered Shares so declined to the other Shareholders who have notified their willingness to take all or any of such Shares in accordance with the terms of the offer and in case of competition, pro rata (as nearly as possible) according to the number of Shares and RCPS held by the other Shareholders.

10. Transfers, Acquisitions and Disposal of Shares

10.1 Pre-emption Rights

10.1.1

The rights of the Shareholders to sell, transfer, assign, pledge, charge, encumber or otherwise dispose of their shareholding in the Company (or any part thereof) shall be subject to the restrictions and provisions set out below :

(a)

In the event any Shareholder desires to dispose of all or any portion of their shareholding in the Company pursuant to a bona-fide third party offer for the shares (“Transferor”), the Transferor shall first afford the other Shareholders (“the Transferees”) a right of first refusal with regard to those shares (“the Relevant Shares”) in proportion to such Transferee’s shareholding in the Company. In this regard, the Transferor shall give the Transferees written notice (hereinafter called a “Transfer Notice”) of the

(b)	Transferor’s intention to dispose of the Relevant Shares, which notice shall include the proposed transferee, the number of shares to be transferred, the price per share, and the terms of payment.

(c)

Upon receipt of the Transfer Notice, the Transferees shall have the option, but not the obligation, to purchase the Relevant Shares at either (i) the same terms and conditions price for the Relevant Shares as set forth in the Transfer Notice, or (ii) to request that the Shareholders appoint an independent firm (at the cost and expense of the Transferor) to determine the sale price per Relevant Share in accordance with the shareholders funds or the net tangible assets (whichever is lower) of the Company as at the date of the Transfer Notice (“the Prescribed Price”).

(d)

In the event the Transferees determine to accept the terms contained in the Transfer Notice or upon the determination of and purchase of the Relevant Shares at the Prescribed Price, the Relevant Shares shall promptly be offered by the Transferor by notice in writing to the Transferees (and if there is more than one Transferee, to each Transferee in proportion to such Transferee’s shareholding in the Company) for purchase. Such offer shall be open for acceptance at any time within the Prescribed Period. The Prescribed Period shall commence on the date that :

(i)	the Transferees notify the Transferor of their acceptance of the offer to purchase the Relevant Shares on the terms contained in the Transfer Notice; or

(ii)	the Prescribed Price is determined;

and will expire sixty (60) days thereafter, after either (i) or (ii) as applicable. The Transferee(s) so accepting the offer shall hereinafter be called the “Purchaser(s)”.

(e)

If there is more than one Purchaser, each Purchaser shall have the right to purchase the Relevant Shares pro rata in accordance with the ratio that his shareholding bears to the aggregate shareholdings of all the Purchasers provided that the said Purchaser must purchase all the Relevant Shares offered to him. Upon acceptance of such offer by the Purchasers within the Prescribed Period, the Transferor shall be bound to sell the Relevant Shares to the Purchasers as set forth above. The sale and purchase of the Relevant Shares shall be completed in accordance with the provisions herein.

(f)

If the offer of the Relevant Shares shall not be accepted by the Transferees, then the Transferor shall be at liberty to transfer or dispose of the Relevant Shares within a period of three (3) months from the expiry of the Prescribed Period to the person identified in the Transfer Notice and in accordance with the terms thereof, subject to Clause 10.1.2 below.

(g)

Any transfer, disposal or sale of shares contemplated by this Clause 10.1.1 shall be subject to the approval(s) of the Public Authorities should such approval be required in law or in practice. Completion and payment of the Prescribed Price shall take place not less than three (3) days nor more than ten (10) Business Days after the date of the receipt of such approval(s) of the Public Authorities.

(h)

(i)	Any transfer, disposal or sale of shares contemplated by Clause 10.1(e) to a third party purchaser shall be further subject to such third party purchaser entering into a deed or other suitable documentation agreeing to be bound by all the terms of this Agreement.

(j)	The procedures and pre-emption rights under this Clause 10 may be waived in writing by the Shareholders.

10.1.2

Pursuant to Clause 10.1.1(e), if the Existing Shareholder wishes to sell its shares to a third party, the Existing Shareholder shall ensure that the Investor be entitled (but not obliged) to sell any part of its holding of Shares to the third party on no less favourable terms and conditions as are applicable to the Existing Shareholder. Upon any exercise by the Investor of this entitlement within 30 days from the date of notice by the Existing Shareholder of such entitlement of the Investor, the Existing Shareholder shall not transfer or sell any of its shares to the third party unless the relevant shares of Investor are so purchased by the third party.

10.1.3

All third parties who acquire shares in the Company under this Clause 10.1 shall enter into a deed of ratification and accession under which the third party shall agree to be bound by the obligations, and shall be entitled to the benefit, of this Agreement.

11 Put Options

11.1 Investor’s Put Right for shares in the Existing Shareholder

As a conditions precedent, the Existing Shareholder will grant to MTDC an option to sell all the RCPS held by MTDC to the Existing Shareholder upon the terms and conditions of the Put Agreement to be entered into between the Existing Shareholder and MTDC.

11.2 Investor’s Put Option for Conversion Shares

The Investor shall have the option to require the Existing Shareholder to purchase all (but not less than all) of the Conversion Shares held by the Investor, upon thirty (30) days’ notice in writing to the Existing Shareholder. The price payable shall be calculated based on the price of USD225 for each Conversion Share, such price compounded at the rate of 6% per annum with yearly rests, up to the date of exercise of the option, and at the discretion of the Existing Shareholder, may be satisfied by either cash or the issuance of shares in the Existing Shareholder. The option shall be exercisable any time between 1 January 2011 and 31 December 2011 and subject to the following:

(a)

the share price of the Existing Shareholder’s shares is below USD2.25; or

(b)

due to any reasons attributable to the Existing Shareholder, the Investor is unable to exercise its rights under the Put Agreement.

12. Duration and Termination

Subject to the provisions of this Clause 12 and Clause 2.4, this Agreement shall take effect without limit in point of time. If the Investor or the Existing Shareholder sells or transfers all of its shares in the Company or if the Investor redeems or exchanges all the RCPS to the shares in the Existing Shareholder, in accordance with the provisions of this Agreement or the Articles (to the extent not inconsistent with this Agreement) or the Put Agreement respectively, it shall be released from all of its rights and obligations under this Agreement and cease to be a party to this Agreement, and all obligations of that Party and all entitlements and requirements relating to that Party under this Agreement will cease. If following any such sale, transfer, redemption or exchange, two or more parties continue to be bound by this Agreement, this Agreement shall continue in full force and effect as between those parties.

13. Previous Agreements and Prevalence of Agreement

13.1	This Agreement and the documents referred to in its provisions are in substitution for all previous agreements between all or any of the parties and contain the whole agreement between the parties relating to the subject matter of this Agreement.

13.2

If, during the continuance of this Agreement, there is any conflict between this Agreement and the Articles, the provisions of this Agreement shall prevail between the parties. In the event of such conflict arising, the parties shall procure and take all necessary steps including effecting such alteration to the Articles as may be necessary to resolve such conflict.

14. Remedy on an Event of Default

14.1	Each of the following will be regarded as an Event of Default:

(a)

either of the Shareholders committing a breach of its obligations under this Agreement and, in the case of a breach capable of remedy, failing to remedy the same within twenty one (21) days of being specifically required in writing so to do by the other Shareholder; or

(b)

any distress, execution, sequestration or other process being levied or enforced upon or sued out against the property of any of the Shareholders which is not discharged within ten (10) days; or

(c)

any encumbrancer taking possession of or a receiver or trustee being appointed over the whole or any part of the undertaking, property or assets of any of the Shareholders; or

(d)

the making of an order or the passing of a resolution for the winding up of any of the Shareholders, otherwise than for the purpose of a reconstruction or amalgamation without insolvency or previously approved by the other Shareholder (such approval not to be unreasonably withheld).

14.2	In the event of an Event of Default taking place,

(a)

the non-defaulting Shareholder shall be entitled to terminate this Agreement; or

(b)

the deadlock provisions referred to in clause 16 shall apply,

without prejudice to any rights or remedies the non-defaulting Shareholder may have against the defaulting Shareholder for any antecedent breach.

14.3	Notwithstanding any provision in this Agreement to the contrary, this Agreement shall remain in full force and effect for so long as shall be necessary to fulfil and give effect to the arrangements and undertakings contained in this Agreement.

14.4

Termination of this Agreement for any cause in accordance with the provisions of this Agreement shall not release any Shareholder from any liability which at the time of termination has already accrued to the other or which thereafter may accrue in respect of any act or omission prior to such termination or which has accrued in consequence of this clause.

15. Confidentiality

Parties shall :

(a)

ensure the confidentiality of this Agreement and the transactions contemplated in this Agreement;

(b) not disclose any provision of this Agreement except :

(i)

where required by law or any relevant governmental regulatory body or competent authority;

(ii) to any financier or professional adviser acting for the party; or

(iii)

the information is public knowledge otherwise than as a consequence of breach of this Clause.

The Existing Shareholder and the Company are permitted to disclose the names of the Parties or make reference to the Parties contributions to the Company. For purposes deemed necessary for the furtherance of the Business, the confidentiality obligation in this Agreement does not cover the names of the Parties and their respective interests in the Company.

This restriction continues to apply after the expiration or sooner termination of this Agreement without limit in point of time but ceases to apply to information or knowledge which may properly come into the public domain through no fault of the Party so restricted.

16. Deadlock

16.1 Disputes

If the Shareholders or their respective representatives are unable to reach agreement in relation to any reserved matter provided for in Clause 7.4 or there is an Event of Default pursuant to Clause 14 or otherwise in relation to any matter of material importance to the future conduct of the Business, the matter shall be referred in the first instance to ▇▇▇▇▇▇ ▇▇▇▇▇▇ on behalf of the Existing Shareholder and to the Chief Executive Officer of MTDC on behalf of the MTDC for resolution. ▇▇▇▇▇▇ ▇▇▇▇▇▇ and the Chief Executive Officer of MTDC shall endeavour to resolve any disagreement in the best interest of the Company as a whole.

16.2 Artificial Deadlock

In no circumstances shall any of the Shareholders create an artificial deadlock for the purposes of this Clause 16. An artificial deadlock shall be a deadlock caused by any Shareholder voting against an issue or proposal in circumstances where the approval of the same is required to enable the Company to carry on the Business properly and efficiently.

17. Further Assurance

Each party shall execute and do all such documents and things as are necessary to carry this Agreement into effect or to give full effect to this Agreement.

18. Remedies

If a Party does not comply with its obligations under this Agreement, the other Party is entitled to the remedy of specific performance and injunctive relief (as may be applicable), and monetary compensation by itself is not an adequate remedy.

19. Waiver and Variation

19.1 Rights not affected

The rights which each Party has under this Agreement shall not be prejudiced or restricted by any delay in exercising or failure to exercise any right or remedy under this Agreement. Unless otherwise agreed in writing, no waiver by any party in respect of a breach shall operate as a waiver in respect of any subsequent breach.

19.2 Cumulative rights and remedies

The rights and remedies provided in this Agreement are in addition to, and do not exclude or limit, any rights or remedies provided by law.

19.3 Variation

This Agreement shall not be varied unless the variation is expressly agreed in writing by each Party.

20. Severability

If any provision of this Agreement is void or unenforceable, it shall be regarded as deleted from this Agreement, and the remaining provisions shall continue to apply.

21. Continuing Effect

Notwithstanding the completion of the transaction contemplated in this Agreement, the provisions of this Agreement shall continue to survive or subsist so long as may be necessary for the purpose of giving effect to each of them.

22. Time

Time wherever mentioned in this Agreement shall be of the essence of this Agreement.

23. Legal Relationship

Nothing in this Agreement shall create, or be regarded as creating, a partnership or the relationship of employer and employee between the Parties. Neither Party has any authority to bind the other in any way.

24. Costs and Expenses

The Existing Shareholder and/or the Company shall bear all fees, costs and expenses of the Investor’s solicitors in connection with this Agreement which shall not exceed RM10,000.

25. Assignment; Successors

25.1 Assignment

Parties may not assign or otherwise deal with its respective rights or benefits under this Agreement without the prior written consent of the other Parties.

25.2 Successors and assigns

This Agreement shall be binding upon the parties and their respective successors, permitted assigns and personal representatives.

26. Notices

Without affecting any other effective mode of service, any notice given under this Agreement :

(a)

must be in writing and may be delivered personally or sent by registered post to the intended recipient at the address shown below or the address last notified by the intended recipient to the sender :

For the Investor :

MTDC

Level 8-9, Menara Yayasan Tun Razak,

▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇,

▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇

Attn: Dato’ ▇▇▇▇▇ b. Alias

Tel: ▇▇-▇▇▇▇ ▇▇▇▇

Fax: ▇▇-▇▇▇▇ ▇▇▇▇

For the Existing Shareholder:

Wafergen Bio-Systems Inc

Bayside Technology Center,

▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇,

▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇, ▇▇▇

Attn : ▇▇▇▇▇▇ ▇▇▇▇▇▇

Tel : ▇▇ (▇▇▇) ▇▇▇-▇▇▇▇

Fax : ▇▇ (▇▇▇) ▇▇▇-▇▇▇▇

For the Company:

Wafergen Biosystems (M) Sdn Bhd (formerly known as Global Dupleks Sdn Bhd)

c/o Wafergen Bio-Systems Inc

Bayside Technology Center,

▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇,

▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇, ▇▇▇

Attn : ▇▇▇▇▇▇ ▇▇▇▇▇▇

Tel : ▇▇ (▇▇▇) ▇▇▇-▇▇▇▇

Fax : ▇▇ (▇▇▇) ▇▇▇-▇▇▇▇

(b)

must be signed; and

(c)

will be taken to be duly given or made :

(i)

(in the case of delivery in person) when delivered, received or left at the above address; and

(ii)

(in the case of delivery by registered post) 48 hours after posting, and in proving service it shall only be necessary to prove that the communication was contained in an envelop which was duly addressed and posted in accordance with this Clause,

but if delivery, receipt or service occurs, or will be taken to occur, on a day on which business is not generally carried on in the place to which the communication is sent or is later than 4 p.m. (local time) it will be taken to have been duly given or made at the commencement of business on the next day on which business is generally carried on in the place.

27. Entire agreement

This Agreement is the entire agreement between the Parties in respect of its subject matter and supersedes all previous agreements with respect to its subject matter.

28. Counterparts

This Agreement may be executed in any number of counterparts, and all counterparts taken together constitute one and the same instrument.

29. Governing Law and Jurisdiction

This Agreement is governed by the laws of Malaysia, and each party submits to the non-exclusive jurisdiction of the courts exercising jurisdiction in Malaysia.

SCHEDULE 1

Principal Terms of the RCPS

1. Subscription Price and par value

The subscription price for each RCPS shall be Ringgit Malaysia equivalent to USD2.25 calculated at the prevailing exchange rate on the on the date payment of the Subscription Price is effected . Each RCPS shall have a par value of RM0.01.

2. Premium

Each RCPS shall be issued at a premium being the difference between the Subscription Price and the par value of RM0.01.

3. Dividend Provision

There is no specific dividend rate attached to the RCPS and the Company is not obliged to declare and pay any dividend while the Investor is holding the RCPS.

4. Liquidation Preference

In the event of any liquidation, dissolution or winding up of the Company, the holders of the RCPS will be entitled to receive in preference to the holders of Shares, the relevant Subscription Price paid for the RCPS plus all accrued but unpaid dividends and dividends in arrears, if any.

5. Conversion

Each holder of the RCPS will have the right, at the option of the holder at any time, to convert all or part of the RCPS into such number of Shares at a conversion ratio of one hundred-to-one (100 RCPS : 1 Share).

The conversion is to be effected by way of consolidating the par value of every one hundred RCPS of RM0.01 each, into the total par value of RM1.00 of each Share.

To effect the above conversion, a conversion notice shall be sent by the holder(s) of the RCPS to the Company not less than thirty (30) days before the intended date of conversion. Such notice shall be in writing and shall fix the date and the time for the conversion.

The Company may from time to time consult with, and make proposals to, the holder(s) of RCPS in relation to the exercise of the holder(s)’ entitlement to convert the RCPS.

Completion of the conversion of the RCPS into Conversion Shares shall be effected at the registered office of the Company unless agreed otherwise by the holder(s) of the RCPS and the Company. On the date fixed for conversion, the holder(s) of the RCPS shall deliver to the Company the share certificate(s) for the relevant RCPS in exchange for share certificates in relation to the relevant amount of Conversion Shares resulting from the conversion of those RCPS. If any share certificate so

delivered to the Company relates to any RCPS which are not to be converted on that day, a fresh share certificate for those RCPS shall be immediately issued by the Company to such holder(s).

6. [Deleted]

7. Redemption Rights

The holders of the RCPS may at any time after the Subsequent Closing by giving a thirty (30) day notice of redemption in such form as may be acceptable to the Company (“Notice of Redemption”), redeem any or all RCPS registered in the name of the holder of the RCPS. The RCPS will be redeemable from funds legally available for distribution at a par value of RM0.01 with premium equivalent to the difference between the Subscription Price and the par value of RM0.01 per RCPS plus all accrued but unpaid dividends and dividends in arrears, if any (“Redemption Price”).

All redemption of the RCPS shall be effected at the registered office of the Company unless agreed otherwise by the holder(s) of the RCPS and the Company. On the date fixed for redemption, the holder(s) of the RCPS shall deliver to the Company the share certificate(s) for the relevant RCPS in exchange for payment in cash (by way of bank draft or any other manner acceptable to the holder(s)) by the Company of the aggregate Redemption Price for the time being payable for those RCPS. If any share certificate so delivered to the Company relates to any RCPS which are not to be redeemed on that day, a fresh share certificate for those RCPS shall be issued by the Company to such holder(s).

No RCPS redeemed by the Company shall be capable of reissue.

8. Voting Rights

The holder of the RCPS will be entitled to the voting rights as referred to in Section 148(2) of the Act.

9. Protective Provisions

Without the approval of the holders of at least a majority of the RCPS, the Company will not take any action, whether by merger, consolidation or otherwise, that:

(a)	effects a sale, lease, license or other disposition of all or substantially all of the Company’s assets, property or business or undertakings;

(b)	effects or enters into any agreement regarding any transaction, or series of transactions, which results in the holders of the RCPS prior to the transaction owning less than 50% of the voting power of the Company’s RCPS after the transaction(s),

(c)	alters or changes the rights, preferences or privileges of the RCPS,

(d)	increases or decreases the number of authorized the RCPS,

(e)

(f)	authorises the issuance of securities having a preference over or on a parity with the RCPS,

(g)	changes the number of directors,

(h)	amends, modifies or repeals the Memorandum of Association and/or Articles of the Company in a manner which adversely affects the holders of the RCPS,

(i)	effects any recapitalization or reorganization, or any voluntary or involuntary liquidation under applicable bankruptcy or reorganization legislation, or any dissolution, liquidation, or winding up of the Company,

(j)	declares or pays dividends on or makes any distributions with respect to any share capital of the Company.

For purposes of these protective provisions, any reference to the Company will be deemed to include any subsidiary of the Company.

10. No Variation

The rights attached to the RCPS shall not be varied, modified or deleted unless in accordance with paragraph 9 above.

[The remainder of this page is intentionally left blank]

SCHEDULE 2

Representations and Warranties

1. Representations and Warranties by the Investor

The Investors warrant to the Company as follows.

1.1

Capacity and Authority

The Investor is duly incorporated and validly exist under the laws of Malaysia and has the power to own its assets and carry on its business as now being conducted.

1.2

Power to execute this Agreement

(a)

The Investor has the right, power and authority, and have taken or will take all action necessary, to validly execute, deliver and exercise its right, and perform its obligations under this Agreement;

(b)

Other than those set out in this Agreement, no other consent, approval, authorization or other order of any court, regulatory body, administrative agency or other order of any other governmental body is required for the execution and delivery by the Investor of this Agreement or the performance by the Investor of the transactions contemplated under this Agreement;

(c)

This Agreement is a valid and binding obligation of the Investor and is enforceable against the Investor in accordance with its terms;

(d)

The execution, delivery and performance of this Agreement will not violate any judgment, order or decree to which the Investor are subject and will not be inconsistent with any constitutional documents or contracts to which the Investor are a party to or otherwise binding on the Investor; and

(e)

There is no action, proceeding, claim or investigation pending against the Investor before any court or administrative authority, which, if determined against the Investor, may reasonably be expected to have a material adverse effect on the Investor’s ability to perform the obligations hereunder.

2.	Representations and Warranties by the Existing Shareholder and the Company

The Existing Shareholder and the Company warrant to the Investor as follows.

2.1

Capacity and Authority

The Company is duly incorporated and validly exists under the laws of Malaysia and has the power to own its assets and carry on the Business.

2.2

Power to execute this Agreement

(a)

The Existing Shareholder and Company have the right, power and authority, and has taken or will take all action necessary, to validly execute, deliver and exercise its right, and perform its obligations under this Agreement;

(b)

Other than those set out in this Agreement, no other consent, approval, authorization or other order of any court, regulatory body, administrative agency or other order of any other governmental body is required for the execution and delivery by the Existing Shareholder and the Company of this Agreement or the performance by the Existing Shareholder and the Company of the transactions contemplated under this Agreement;

(c)

This Agreement is a valid and binding obligation of the Existing Shareholder and the Company and after fulfillment of the conditions precedent is enforceable against the Existing Shareholder and the Company in accordance with its terms;

(d)

The execution, delivery and performance of this Agreement will not violate any judgment, order or decree to which the Existing Shareholder and the Company is subject and save as otherwise disclosed, will not be inconsistent with any constitutional documents or contracts to which the Existing Shareholder and/or the Company is a party to or otherwise binding on the Existing Shareholder and/or the Company; and

(e)

There is no action, proceeding, claim or investigation pending against the Existing Shareholder and/or the Company before any court or administrative authority, which, if determined against the Existing Shareholder and/or the Company, may reasonably be expected to have a material adverse effect on the Existing Shareholder and the Company’s ability to perform the obligations hereunder.

[The remainder of this page is intentionally left blank]

SCHEDULE 3

Subscription Notice

From : Wafergen Biosystems (M) Sdn Bhd

To : [Investor]

SHARE SUBSCRIPTION AND SHAREHOLDERS AGREEMENT DATED ** (“Subscription Agreement”)

We refer to the Subscription Agreement made between yourselves, the Existing Shareholder, and us. Terms defined in the Subscription Agreement have the same meanings when used in this notice.

We hereby give you notice, in accordance with the terms and conditions of the Subscription Agreement, of your required subscription for 444,444 of the RCPS at a total Subscription Price of USD1,000,000 (equivalent to RM ** based on the exchange rate as at **), such subscription to be completed on [date] at [time], being the [Initial Closing/Subsequent Closing] (delete whichever is not applicable).

Dated :

Yours faithfully

For and on behalf of

Wafergen Biosystems (M) Sdn Bhd

By:

Name:

Title:

Execution

Executed as an Agreement.

Signed for and on behalf of WaferGen Bio-systems, Inc (WGBS.OB) in the presence of:
/s/ Nazri Bin Said		/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
Witness		Signatory
Name: Nazri Bin Said		Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇
NRIC No: 550571025665		Designation: CEO
		NRIC No:

Signed for and on behalf of Malaysian Technology Development Corporation Sdn Bhd (Company No 235796-U) in the presence of:
/s/ Mohdazmi Mahd ▇▇▇▇		/s/ ▇▇▇▇▇ Alias
Witness		Signatory
Name: Mohdazmi Mahd ▇▇▇▇		Name: ▇▇▇▇▇ Alias
NRIC No: 641209-11-5213		Designation: CEO
		NRIC No: 671012-10-5297

Signed for and on behalf of Wafergen Biosystems (M) Sdn Bhd (formerly known as Global Dupleks Sdn Bhd) (Company No 795066-H) in the presence of:
/s/ Nazri Bin Said		/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
Witness		Signatory
Name: Nazri Bin Said		Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇
NRIC No: 550571025665		Designation: CEO
		NRIC No:

Dated 8 May 2008 Between Wafergen Bio-Systems Inc and Malaysian Technology Development Corporation Sdn Bhd and Wafergen Biosystems (M) Sdn Bhd (formerly known as Global Dupleks Sdn Bhd)

Document Metadata

Document Metadata

Table of Contents